Edward Maldonado, MD
Assistant Professor
Medicine
School of Medicine

I am a Medical Oncologist within the Division of Hematology/Oncology at the University of California, San Francisco. My clinical practice focuses on care of adults with genitourinary cancers, including prostate, bladder, kidney, and testicular cancer.

Show full bio (42 words) Hide full bio

My research interests include clinical trials to evaluate promising treatments for patients with genitourinary cancers, with particular interests in advanced prostate cancer and DNA damage repair therapies. I have also participated in quality improvement projects centered around fertility preservation and medical education.

Awards

Show all (6) Hide

• UCSF Internal Medicine Residency Hematology/Oncology Fellow Teaching Award, University of California, San Francisco, Department of Medicine, Division of Internal Medicine, 2023
• UCSF Rachel Pearline Award: awarded to a hematology/oncology fellow who demonstrates an extraordinary commitment to patient care and embodies Rachel's deep humanism., University of California, San Francisco, Department of Medicine, Division of Hematology and Medical Oncology, 2022
• OHSU Professional Board Outstanding Contribution to Education and Research, Oregon Health and Science University, Department of Medicine, Division of Internal Medicine, 2021
• OHSU Medical Housestaff Teaching Award, Oregon Health and Science University, Department of Medicine, Division of Internal Medicine, 2020
• Thomas J. & Nancy Fitzgerald Stack Award: a merit-based humanism award in recognition of integrity, dedication, and selflessness in caring for patients., Oregon Health and Science University, Department of Medicine, Division of Internal Medicine, 2020
• Becky Houck Award for Outstanding Teaching Assistance, Mentoring, and Service, University of Portland, Department of Biology, 2012

Education & Training

Show all (7) Hide

• University of California, San Francisco, San Francisco, CA Fellowship in Hematology/Medical Oncology 2024
• University of California, San Francisco, San Francisco, CA Chief Fellow in Hematology/Medical Oncology 2023
• Oregon Health and Science University, Portland, OR. Chief Resident in Internal Medicine 2021
• Oregon Health and Science University, Portland, OR. Residency in Internal Medicine 2020
• Oregon Health and Science University, Portland, OR. Internship in Internal Medicine 2018
• MD Creighton University School of Medicine, Omaha, NE. 2017
• BS Biology (Minor in Chemistry) University of Portland, Portland, OR. 2012

Publications (10)

Top publication keywords:
Pneumonia, ViralCell Cycle ProteinsCoronavirus InfectionsProtein-Tyrosine KinasesLymphoma, Mantle-CellPyrazolesCarcinoma, Renal CellCarcinoma, Transitional CellVenous ThromboembolismObservational Studies as TopicBetacoronavirusHodgkin DiseaseHistone-Lysine N-MethyltransferaseFibrinolytic AgentsPyrimidinones

• A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170).
  Cancer research communications 2024 Maldonado E, Rathmell WK, Shapiro GI, Takebe N, Rodon J, Mahalingam D, Trikalinos NA, Kalebasty AR, Parikh M, Boerner SA, Balido C, Krings G, Burns TF, Bergsland EK, Munster PN, Ashworth A, LoRusso P,…
• Impact of Squamous Histology on Clinical Outcomes and Molecular Profiling in Metastatic Urothelial Carcinoma Patients Treated With Immune Checkpoint Inhibitors or Enfortumab Vedotin.
  Clinical genitourinary cancer 2023 Jindal T, Zhang L, Deshmukh P, Reyes K, Chan E, Kumar V, Zhu X, Maldonado E, Feng S, Johnson M, Angelidakis A, Kwon D, Desai A, Borno HT, Bose R, Wong A, Hong J, Carroll P, Meng M, Porten S, Aggarwal …
• Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer.
  Frontiers in oncology 2023 Jindal T, Zhu X, Bose R, Kumar V, Maldonado E, Deshmukh P, Shipp C, Feng S, Johnson MS, Angelidakis A, Kwon D, Borno HT, de Kouchkovsky I, Desai A, Aggarwal R, Fong L, Small EJ, Wong A, Porten S, Chou…
• Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.
  Blood advances 2021 Bond DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, …
• Antithrombotic Therapies in COVID-19 Disease: a Systematic Review.
  Journal of general internal medicine 2020 Maldonado E, Tao D, Mackey K

Show all (5 more) Hide

• Estimation of US patients with cancer who may respond to cytotoxic chemotherapy.
  Future science OA 2020 Maldonado EB, Parsons S, Chen EY, Haslam A, Prasad V
• Comparison of Drugs Used for Adjuvant and Metastatic Therapy of Colon, Breast, and Non-Small Cell Lung Cancers.
  JAMA network open 2020 Parsons S, Maldonado EB, Prasad V
• Refractory Autoimmune Cytopenias Treated With Venetoclax.
  HemaSphere 2019 Gordon MJ, Maldonado E, Danilov AV
• Treatment Patterns and Outcomes in Early-stage Hodgkin Lymphoma in the Elderly: A National Cancer Database Analysis.
  Clinical lymphoma, myeloma & leukemia 2017 Goyal G, Maldonado EB, Fan TJ, Kanmanthareddy A, Silberstein PT, Go RS, Armitage JO
• The human immunodeficiency virus transactivator Tat interacts with the RNA polymerase II holoenzyme.
  Molecular and cellular biology 1997 Cujec TP, Cho H, Maldonado E, Meyer J, Reinberg D, Peterlin BM